JP2004537581A5 - - Google Patents

Download PDF

Info

Publication number
JP2004537581A5
JP2004537581A5 JP2003518580A JP2003518580A JP2004537581A5 JP 2004537581 A5 JP2004537581 A5 JP 2004537581A5 JP 2003518580 A JP2003518580 A JP 2003518580A JP 2003518580 A JP2003518580 A JP 2003518580A JP 2004537581 A5 JP2004537581 A5 JP 2004537581A5
Authority
JP
Japan
Prior art keywords
acid
alanine
arginine
derivative
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003518580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004537581A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/026796 external-priority patent/WO2003013574A1/en
Publication of JP2004537581A publication Critical patent/JP2004537581A/ja
Publication of JP2004537581A5 publication Critical patent/JP2004537581A5/ja
Pending legal-status Critical Current

Links

JP2003518580A 2001-08-08 2002-08-02 メラニン濃縮ホルモン拮抗物質 Pending JP2004537581A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31092801P 2001-08-08 2001-08-08
PCT/US2002/026796 WO2003013574A1 (en) 2001-08-08 2002-08-02 Melanin-concentrating hormone antagonists

Publications (2)

Publication Number Publication Date
JP2004537581A JP2004537581A (ja) 2004-12-16
JP2004537581A5 true JP2004537581A5 (enExample) 2005-12-22

Family

ID=23204651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003518580A Pending JP2004537581A (ja) 2001-08-08 2002-08-02 メラニン濃縮ホルモン拮抗物質

Country Status (5)

Country Link
US (1) US7335723B2 (enExample)
EP (1) EP1416951A1 (enExample)
JP (1) JP2004537581A (enExample)
CA (1) CA2456964A1 (enExample)
WO (1) WO2003013574A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
CN108137651B (zh) * 2015-10-23 2022-02-22 富士胶片株式会社 环肽、亲和层析载体、标记抗体、抗体药物复合物及药物制剂
WO2017069269A1 (ja) * 2015-10-23 2017-04-27 富士フイルム株式会社 環状ペプチド、アフィニティクロマトグラフィー担体、標識化抗体、抗体薬物複合体、および医薬製剤
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
CA3161341A1 (en) 2019-12-11 2021-06-17 Masoud Fakhr Tavazoie Methods of treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049655A (en) 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
US5849708A (en) 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
WO2001057070A1 (en) 2000-02-03 2001-08-09 Merck & Co., Inc. Melanin-concentrating hormone analogs
EP1485405A4 (en) 2001-05-31 2005-09-21 Merck & Co Inc MELANIN CONCENTRATING HORMONE ANALOG
CA2473229A1 (en) 2002-01-09 2003-07-24 Merck & Co., Inc. Selective melanin-concentrating hormone type -1 receptor agonists

Similar Documents

Publication Publication Date Title
JP2004537581A5 (enExample)
JP2002523466A5 (enExample)
JP2010536714A5 (enExample)
JP2013155195A5 (enExample)
JP2013533864A5 (enExample)
KR970042553A (ko) 캠프토테신 유도체
KR101328851B1 (ko) 개선된 특성을 가지는 재구성된 계면활성제
CN102300580A (zh) 二肽连接的药剂
JP2011511753A5 (enExample)
JP2004521123A5 (enExample)
JP2002526454A5 (enExample)
JP2015532283A5 (enExample)
JP2020502051A5 (enExample)
JP2013500990A5 (enExample)
JP2011508742A5 (enExample)
HRP20161614T1 (hr) Terapijska sredstva za smanjenje razina paratiroidnog hormona
CA2121724A1 (en) Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
JP2024520861A (ja) 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体
EP3074032B1 (en) Fatty acid derivatives of dimeric inhibitors of psd-95
JP2011523935A5 (enExample)
RU2010111139A (ru) Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства
JPH0773479B2 (ja) 栄養素組成物
JP7809117B2 (ja) Glp-1/glp-2デュアルアゴニストの医薬組成物
JP2009533355A5 (enExample)
JP2004535461A5 (enExample)